IGC Pharma Inc. (IGS1)
XSTU 
Summary
IGS1 Chart
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.02 per share a year ago.
All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for Oct. 24: IGC, ASM and More
IGC, SCRYY, RY, UVE and ASM have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 24, 2025.
IGC Pharma Inc. (IGS1) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
IGC Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Ram Mukunda CEO | XSTU Exchange | US45408X3089 ISIN |
| US Country | 67 Employees | - Last Dividend | 19 Apr 2013 Last Split | 13 Apr 2006 IPO Date |
Overview
IGC Pharma, Inc., initially known as India Globalization Capital, Inc., is a transformative clinical stage biotechnology firm that has carved out a niche in developing innovative cannabinoid-based treatments. With its rebranding in March 2023, IGC Pharma has sharpened its focus on addressing a variety of diseases and conditions that significantly impact human health, such as Alzheimer's disease, dysmenorrhea, premenstrual syndrome (PMS), and chronic pain. Founded in 2005 and based in Potomac, Maryland, the company leverages cutting-edge science to pioneer treatments aimed at improving the quality of life for patients across these challenging conditions.
Products and Services
IGC Pharma, Inc. is at the forefront of research and development in the realm of cannabinoid-based therapeutics, with a robust pipeline that includes investigational drug assets and wellness brands.
- IGC-AD1
- TGR-63
- Holief
This investigational drug is currently in a Phase 2B clinical trial and is designed as a potential treatment for agitation in dementia due to Alzheimer's disease. IGC-AD1 represents IGC Pharma’s commitment to addressing the complexities of Alzheimer’s, focusing on one of its most distressing manifestations.
Still in the pre-clinical development stage, TGR-63 is another promising investigational asset targeting Alzheimer's disease. This drug is part of IGC Pharma's strategic efforts to diversify its portfolio in the fight against neurodegenerative diseases, showcasing the company's dedication to groundbreaking research.
A wellness brand marketed by IGC Pharma, Holief targets women experiencing PMS and menstrual cramps. Emphasizing natural, cannabinoid-based relief, Holief stands as a testament to the company’s initiative to not only focus on clinical therapeutics but also offer wellness products that aid in everyday discomforts associated with menstrual health.
